This episode of Pharma Pulse covers the potential ramifications of a federal government shutdown on FDA operations, Aetna’s newly announced 2026 Medicare Advantage offerings, and new research showing ...
Direct-to-patient delivery requires robust temperature control, real-time visibility, and alignment of packaging, technology, and courier services. Managing temperature control risks involves process ...
According to a new national poll from the PAN Foundation’s Center for Patient Research, 1 in the past 12 months, more than half (54%) of insured adults with commercial insurance have been told by ...
From patent cliffs and government price controls, to self-pay models and staff-model HMOs, a look at the forces that could deflate the bubble—and those factors likely to keep it afloat a while longer.
Amid pressures on pharma to match the lowest international prices, experts warn of “policy laundering” and discriminatory impact.
Dave Malenfant, healthcare supply chain expert, gives his sneak peak into LogiPharma USA.
This episode of Pharma Pulse covers ATA’s warning that telehealth protections are critical to maintaining care access during a potential federal shutdown, new KFF data showing the rapid rise of ...
Dave Malenfant, healthcare supply chain expert, gives his sneak peak into LogiPharma 2025.
How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of proactive chemistry, manufacturing, and controls strategies.
Dave Malenfant, healthcare supply chain expert, discusses the ramifications of a 100% tariff on branded and patented drugs entering the US.
AI integration in supply chains must balance with maintaining human connections and trust with partners. Bayer's digital culture is essential for successful AI adoption, requiring changes in mindset ...
This episode of Pharma Pulse covers the Trump administration’s plan to launch a government-run healthcare website for patients, new data showing gabapentin has become the fifth most prescribed drug in ...